{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:34:07Z","timestamp":1793136847831,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The overall infection rate of\n                      <jats:italic>Stenotrophomonas maltophilia<\/jats:italic>\n                      has markedly increased over the past two decades, with its bloodstream infections being associated with poor clinical outcomes and high mortality rates. In patients with concomitant renal insufficiency, the complexity of anti-infective therapy is further heightened due to limited antibiotic options and altered pharmacokinetics, highlighting the critical importance of individualized treatment strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aims to explore effective clinical treatment strategies for\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      -induced bloodstream infections in patients with renal insufficiency and to provide evidence-based support for optimizing antimicrobial decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We present a case of\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      bloodstream infection occurring in a patient with concomitant renal insufficiency. The choice of antimicrobial agents, dosage modifications, and combination therapy were systematically analyzed based on results from antimicrobial combination testing and observed clinical response. A comprehensive review of relevant literature was also conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Guided by the findings of antimicrobial combination testing, an individualized regimen consisting of ceftazidime-avibactam (CZA) and aztreonam (ATM) was implemented, with dose adjustments tailored according to the patient\u2019s renal function. This approach led to the successful resolution of the infection. The literature review further supports that in patients with renal insufficiency, antimicrobial selection should be guided by considerations including nephrotoxic potential, spectrum of activity, and pharmacokinetic profiles. Combined susceptibility testing emerges as a valuable tool in tailoring effective therapeutic regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The combination of CZA and ATM, guided by antimicrobial susceptibility testing and adjusted according to individual patient characteristics, demonstrated both safety and efficacy in the treatment of\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      bloodstream infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1694228","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:27:35Z","timestamp":1761283655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic challenges in managing Stenotrophomonas maltophilia bloodstream infection in a renal dysfunction patient: a case study and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiongxiong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengshang","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: A systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"Jama."},{"key":"B2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J. antimicrobial chemotherapy."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00297-20","article-title":"Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12941-024-00685-4","article-title":"Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"23","author":"Bostanghadiri","year":"2024","journal-title":"Ann. Clin. Microbiol. antimicrobials."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/antibiotics13070577","article-title":"Stenotrophomonas maltophilia: the landscape in critically ill patients and optimizing management approaches","volume":"13","author":"Carbonell","year":"2024","journal-title":"Antibiotics (Basel Switzerland)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/gb-2008-9-4-r74","article-title":"The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants","volume":"9","author":"Crossman","year":"2008","journal-title":"Genome Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.idnow.2021.01.014","article-title":"Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia","volume":"51","author":"Diarra","year":"2021","journal-title":"Infect. Dis. now."},{"key":"B9","volume-title":"CHINET China bacterial resistance monitoring results","author":"Ding","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17425255.2018.1434142","article-title":"Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia","volume":"14","author":"Falcone","year":"2018","journal-title":"Expert Opin. Drug Metab. toxicology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jinf.2012.01.001","article-title":"Stenotrophomonas maltophilia\u2013the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study","volume":"64","author":"Fihman","year":"2012","journal-title":"J. infection."},{"key":"B13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/antibiotics14030306","article-title":"Rare or unusual non-fermenting gram-negative bacteria: therapeutic approach and antibiotic treatment options","volume":"14","author":"Geremia","year":"2025","journal-title":"Antibiotics (Basel Switzerland)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14787210.2020.1730178","article-title":"Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge","volume":"18","author":"Gil-Gil","year":"2020","journal-title":"Expert Rev. anti-infective Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0164722","DOI":"10.1128\/jcm.01647-22","article-title":"Multicenter evaluation of an MIC-based aztreonam and ceftazidime-avibactam broth disk elution test","volume":"61","author":"Harris","year":"2023","journal-title":"J. Clin. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy."},{"key":"B17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in Stenotrophomonas maltophilia bacteremia - a meta-analysis","volume":"56","author":"Huang","year":"2024","journal-title":"Infect. Dis. (London England)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.3390\/jcm11113085","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with stenotrophomonas maltophilia bacteremia","volume":"11","author":"Kanchanasuwan","year":"2022","journal-title":"J. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12879-025-10636-9","article-title":"Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024","volume":"25","author":"Koh","year":"2025","journal-title":"BMC Infect. diseases."},{"key":"B20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.16718\/j.1009-7708.2023.01.013","article-title":"Expert consensus on antimicrobial synergy testing and reporting of carbapenem-resistant Gram-negative bacteria","volume":"23","author":"Li","year":"2023","journal-title":"Chin. J. Infection Chemotherapy."},{"key":"B21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12866-021-02108-2","article-title":"Avibactam potentiated the activity of both ceftazidime and aztreonam against S","volume":"21","author":"Lin","year":"2021","journal-title":"maltophilia Clin. isolates vitro. BMC Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fiber infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J. antimicrobial chemotherapy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1872208316666220512121205","article-title":"Review on Stenotrophomonas maltophilia: An Emerging Multidrug- resistant Opportunistic Pathogen","volume":"16","author":"Majumdar","year":"2022","journal-title":"Recent patents Biotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199426020-00003","article-title":"Clinical pharmacokinetics of aztreonam","volume":"26","author":"Mattie","year":"1994","journal-title":"update. Clin. pharmacokinetics."},{"key":"B25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QCO.0000000000000975","article-title":"Treatment approaches for severe Stenotrophomonas maltophilia infections","volume":"36","author":"Mojica","year":"2023","journal-title":"Curr. Opin. Infect. diseases."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-\u03b2-lactamase-producing stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00777-17","article-title":"Avibactam restores the susceptibility of clinical isolates of stenotrophomonas maltophilia to aztreonam","volume":"61","author":"Mojica","year":"2017","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cmi.2025.04.031","article-title":"How do I manage a patient with Stenotrophomonas maltophilia infection","volume":"31","author":"Monardo","year":"2025","journal-title":"Clin. Microbiol. infection: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Diseases."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.clinthera.2020.06.005","article-title":"Intravenous compatibility of ceftazidime-avibactam and aztreonam using simulated and actual Y-site administration","volume":"42","author":"O\u2019Donnell","year":"2020","journal-title":"Clin. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1128\/AAC.01485-07","article-title":"Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator","volume":"52","author":"Okazaki","year":"2008","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01433-20","article-title":"Carvalhaes CG and Castanheira M. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrobial Agents chemotherapy."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00658","article-title":"Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia","volume":"6","author":"S\u00e1nchez","year":"2015","journal-title":"Front. Microbiol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. diseases: an Off. Publ. Infect. Dis. Soc. America."},{"key":"B34","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.ijantimicag.2025.107512","article-title":"Cerebrospinal fluid concentrations of ceftaroline and ceftazidime\/avibactam in healthy volunteers: Pharmacokinetics and probability of target attainment","volume":"66","author":"W\u00f6lfl-Duchek","year":"2025","journal-title":"Int. J. antimicrobial agents."},{"key":"B35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3760\/cma.j.issn.0376-2491.2013.16.002","article-title":"Chinese expert consensus on the diagnosis, treatment, and prevention of stenotrophomonas maltophilia infections","volume":"93","author":"Zhou","year":"2013","journal-title":"Chin. Med. J"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1694228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:27:37Z","timestamp":1761283657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1694228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":36,"alternative-id":["10.3389\/fcimb.2025.1694228"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1694228","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"1694228"}}